ProQR Therapeutics (PRQR) Non-Current Assets (2013 - 2026)

ProQR Therapeutics has reported Non-Current Assets for 14 years, with the latest figure at $14.1 million in Q1 2026.

• Quarterly Non-Current Assets fell 1.43% year-over-year to $14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.0 million (down 5.97% YoY) and the FY2025 annual result came in at $14.7 million, down 2.51% from the prior year.
• Non-Current Assets eased to $14.1 million in Q1 2026 per PRQR's latest filing, from $14.7 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $19.9 million in Q1 2022 and troughed at $14.1 million in Q1 2026.
• A 5-year average of $16.9 million and a median of $17.5 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets sank 99.98% in 2022, then climbed 6.24% in 2023.
• Over 5 years, Non-Current Assets stood at $17.2 million in 2022, then increased by 5.68% to $18.2 million in 2023, then slipped by 17.05% to $15.1 million in 2024, then declined by 2.51% to $14.7 million in 2025, then decreased by 4.03% to $14.1 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $14.1 million, $14.7 million, and $15.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.